DE69632632D1 - Behandlungsverfahren für darmadenome - Google Patents

Behandlungsverfahren für darmadenome

Info

Publication number
DE69632632D1
DE69632632D1 DE69632632T DE69632632T DE69632632D1 DE 69632632 D1 DE69632632 D1 DE 69632632D1 DE 69632632 T DE69632632 T DE 69632632T DE 69632632 T DE69632632 T DE 69632632T DE 69632632 D1 DE69632632 D1 DE 69632632D1
Authority
DE
Germany
Prior art keywords
darmadenoma
treatment procedure
administration
patient
adenoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69632632T
Other languages
English (en)
Other versions
DE69632632T2 (de
Inventor
Stacia Kargman
Jilly Evans
J Simon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Frosst Canada and Co
Merck Sharp and Dohme LLC
Original Assignee
Merck Frosst Canada and Co
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9603470.7A external-priority patent/GB9603470D0/en
Application filed by Merck Frosst Canada and Co, Merck and Co Inc filed Critical Merck Frosst Canada and Co
Publication of DE69632632D1 publication Critical patent/DE69632632D1/de
Application granted granted Critical
Publication of DE69632632T2 publication Critical patent/DE69632632T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/603—Salicylic acid; Derivatives thereof having further aromatic rings, e.g. diflunisal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Harvester Elements (AREA)
  • Lasers (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Superconductors And Manufacturing Methods Therefor (AREA)
  • Soil Working Implements (AREA)
DE69632632T 1995-07-19 1996-07-15 Behandlungsverfahren für darmadenome Expired - Lifetime DE69632632T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US124095P 1995-07-19 1995-07-19
US1240P 1995-07-19
GB9603470 1996-02-19
GBGB9603470.7A GB9603470D0 (en) 1996-02-19 1996-02-19 Method of treating colonic adenomas
PCT/US1996/011761 WO1997003667A1 (en) 1995-07-19 1996-07-15 Method of treating colonic adenomas

Publications (2)

Publication Number Publication Date
DE69632632D1 true DE69632632D1 (de) 2004-07-08
DE69632632T2 DE69632632T2 (de) 2005-05-25

Family

ID=26308761

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69632632T Expired - Lifetime DE69632632T2 (de) 1995-07-19 1996-07-15 Behandlungsverfahren für darmadenome

Country Status (17)

Country Link
EP (1) EP0839034B1 (de)
KR (1) KR100454624B1 (de)
CN (1) CN1196679A (de)
AT (1) ATE268176T1 (de)
AU (1) AU706089B2 (de)
CA (1) CA2227238C (de)
CZ (1) CZ294516B6 (de)
DE (1) DE69632632T2 (de)
EA (1) EA005073B1 (de)
ES (1) ES2220983T3 (de)
HU (1) HU225506B1 (de)
IL (1) IL122960A (de)
MX (1) MX9800568A (de)
NO (1) NO980221L (de)
NZ (1) NZ312997A (de)
SK (1) SK5298A3 (de)
WO (1) WO1997003667A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6166024A (en) 1995-03-30 2000-12-26 Mayo Foundation For Medical Education And Research Use of topical azathioprine and thioguanine to treat colorectal adenomas
KR20010023256A (ko) * 1997-08-27 2001-03-26 헥살 아게 용해도와 생체 이용성이 개선된 신규의 멜록시캄 의약조성물
NZ509376A (en) * 1998-07-09 2003-10-31 Francis A Nardella Indole or carbazole derivatives for the treatment of chronic lyphocytic leukemia
US7105560B1 (en) * 1999-07-23 2006-09-12 The Regents Of The University Of California Use of etodolac in the treatment of multiple myeloma
US20020035107A1 (en) 2000-06-20 2002-03-21 Stefan Henke Highly concentrated stable meloxicam solutions
AR038957A1 (es) 2001-08-15 2005-02-02 Pharmacia Corp Terapia de combinacion para el tratamiento del cancer
DE10161077A1 (de) 2001-12-12 2003-06-18 Boehringer Ingelheim Vetmed Hochkonzentrierte stabile Meloxicamlösungen zur nadellosen Injektion
CN1659131A (zh) 2002-04-08 2005-08-24 葛兰素集团有限公司 2－((2－烷氧基)－苯基)－环戊－1－烯基)芳香碳－以及杂环羧酸及其衍生物
US8992980B2 (en) 2002-10-25 2015-03-31 Boehringer Ingelheim Vetmedica Gmbh Water-soluble meloxicam granules
GB0225548D0 (en) 2002-11-01 2002-12-11 Glaxo Group Ltd Compounds
EP1568369A1 (de) 2004-02-23 2005-08-31 Boehringer Ingelheim Vetmedica Gmbh Verwendung von Meloxicam zur Behandlung von Atemwegserkrankungen bei Schweinen
AR047894A1 (es) 2004-02-25 2006-03-01 Wyeth Corp Derivados de tiofeno como inhibidores de la proteina tirosina fosfatasa 1b (ptpasa 1b); metodos para su preparacion, composiciones farmaceuticas que los contienen y su uso en el tratamiento de enfermedades mediadas por ptpasa 1b
TW200735866A (en) * 2005-11-18 2007-10-01 Synta Pharmaceuticals Corp Compounds for the treatment of proliferative disorders
BRPI0806898A2 (pt) * 2007-01-19 2015-07-14 Ardea Biosciences Inc Inibidores de mek
CN102647971B (zh) 2009-10-12 2016-03-16 贝林格尔.英格海姆维特梅迪卡有限公司 用于包含美洛昔康的组合物的容器
WO2011107150A1 (en) 2010-03-03 2011-09-09 Boehringer Ingelheim Vetmedica Gmbh Use of meloxicam for the long-term treatment of musculoskeletal disorders in cats
US9795568B2 (en) 2010-05-05 2017-10-24 Boehringer Ingelheim Vetmedica Gmbh Low concentration meloxicam tablets

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1269495A (en) * 1994-01-10 1995-08-01 Merck Frosst Canada Inc. Phenyl heterocycles as cox-2 inhibitors
CA2206978A1 (en) * 1994-12-21 1996-06-27 Merck Frosst Canada Inc. Diaryl-2-(5h)-furanones as cox-2 inhibitors

Also Published As

Publication number Publication date
ATE268176T1 (de) 2004-06-15
IL122960A0 (en) 1998-08-16
IL122960A (en) 2006-07-05
KR19990029066A (ko) 1999-04-15
CA2227238C (en) 2003-10-28
EA199800139A1 (ru) 1998-08-27
AU6496096A (en) 1997-02-18
EP0839034A4 (de) 2002-06-19
CN1196679A (zh) 1998-10-21
CZ15698A3 (cs) 1998-09-16
WO1997003667A1 (en) 1997-02-06
EP0839034B1 (de) 2004-06-02
EA005073B1 (ru) 2004-10-28
HU225506B1 (en) 2007-01-29
NZ312997A (en) 2000-07-28
HUP9901711A2 (hu) 1999-09-28
CA2227238A1 (en) 1997-02-06
AU706089B2 (en) 1999-06-10
MX9800568A (es) 1998-04-30
ES2220983T3 (es) 2004-12-16
CZ294516B6 (cs) 2005-01-12
HUP9901711A3 (en) 2001-02-28
DE69632632T2 (de) 2005-05-25
EP0839034A1 (de) 1998-05-06
NO980221L (no) 1998-03-18
SK5298A3 (en) 1998-12-02
KR100454624B1 (ko) 2004-12-31
NO980221D0 (no) 1998-01-16

Similar Documents

Publication Publication Date Title
DE69632632D1 (de) Behandlungsverfahren für darmadenome
NZ515567A (en) Method for treating chronic pain using MEK inhibitors
PT971713E (pt) Utilizacao de inibidores da colinesterase para tratamento de desordens da atencao
TR199900827T2 (xx) Siklooksigenaz-2 inhibit�rlerinin neoplazinin tedavisinde ve �nlenmesinde kullan�m�.
WO2000040235A3 (en) Treatment of asthma with mek inhibitors
AU2001231763A1 (en) Dosing regimen
TR200000755T2 (tr) Karşıt olma-karşı gelme bozukluğunun tedavisi.
ATE298566T1 (de) Proteintyrosine-kinaseinhibitoren zur behandlung der osteoarthritis
EA199700119A1 (ru) Соединения, оказывающие эффекты на системы, связанные с серотонином
DE69939651D1 (de) Behandlung hyperproliferativer erkrankungen
DK0946166T3 (da) Anvendelse af matrixmetalloproteinaseinhibitorer til fremme af sårheling
DE69831000D1 (de) Verwendung von cytidin und cytosin-enthaltenden verbindungen zur behandlung von reizmittelgelgebrauch
ES2166001T3 (es) Utilizacion de compuestos antimineralcorticoides contra el sindrome de abstinencia de narcoticos.
NO983906L (no) Anvendelse av karboniske anhydraseinhibitorer for behandling av makulµr °dem
DK1305037T3 (da) Smertestillende medikament
HUP9801022A2 (hu) Eljárás aldóz reduktáz inhibítor alkalmazása diabetikus szívizom-betegség megelőzésére vagy megfordítására
EP0756869A3 (de) Verwendung von Duloxetin oder von N-Alkyl-3-phenyl-(2-alkylthiophenoxy)-Propylaminen zur Behandlung von Aufmerksamkeitsstörungen und Hyperaktivität
MX9606494A (es) Compuestos organicos.
EE9700350A (et) COMT-inhibiitorite uus kasutamine ja diabeetiliste vaskulaarsete häirete ärahoidmise meetod
DK1011672T3 (da) Anvendelse af (E)-metanicotin derivater til frembringelse af analgetiske virkninger
ATE306269T1 (de) Behandlung der exzessiven aggressivität mit olanzapine
TR199701613T1 (xx) Selim prostatik hiperplasyan�n tedavisi i�in melatonin agonistleri.
NO982854D0 (no) Nitrogenoksyd (NO) syntetase-inhibitor for Õ behandle eller forebygge type II diabetes
WO2002005796A3 (en) Use of a spla2 inhibitor for the treatment of sepsis
PT971714E (pt) Metodo utilizando inibidores ciclooxigenase-2 no tratamento e prevencao da demencia

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: MERCK & CO., INC., WHITEHOUSE STATION, N.J., US

Owner name: MERCK FROSST COMPANY, HALIFAX, NOVA SCOTIA, CA

8327 Change in the person/name/address of the patent owner

Owner name: MERCK FROSST COMPANY, HALIFAX, NOVA SCOTIA, CA

Owner name: MERCK SHARP & DOHME CORP., NEW JERSEY, N.J., US